To investigate the mechanism of HMGB3 in CRC, we designed siHMGB3-1, siHMGB3-2 and siHMGB3-3 of HMGB3, and we also did stable transgenic overexpression, we validated this in six CRC cell lines and showed that HMGB3 was highest in RKO cells and lowest in HCT8 (Figure 7C), so we selected RKO for knockdown and HCT8 cells for overexpression. This evidence concerns the gene HMGB3 and colorectal carcinoma.